Combined hormone and chemo before surgery for HER2+ breast cancer
Part of Cancer clinical trials.
This trial tests combining hormone therapy with chemotherapy and targeted therapy before surgery for a type of breast cancer that is both hormone-receptor-positive (HR+) and HER2-positive. The goal is to see if this combination works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have newly diagnosed, early-stage (stage IIA to IIIC) breast cancer that hasn't been treated yet.
- Your cancer must test positive for both hormone receptors (HR+) and HER2, based on standard guidelines.
- You must be scheduled to receive at least 4 cycles of a specific chemotherapy regimen called TCHP.
- Your tumor must be classified as Luminal A, Luminal B, or HER2-enriched by a special genetic test (MammaPrint/BluePrint).
- You cannot have had breast cancer in the past 5 years or any other cancer in the past 2 years, and your breast cancer must not be recurrent or stage IV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This trial tests a new approach: combining hormone therapy with chemotherapy before surgery for early-stage breast cancer. It may help shrink the tumor and improve chances of successful treatment.
This trial tests whether adding a targeted therapy (a CDK4/6 inhibitor) to standard hormone therapy can let some people safely skip chemotherapy. It is for early-stage, hormone-positive breast cancer that is also HER2-positive, and aims to reduce side effects while keeping the cancer from coming back.
This trial tests a combination of three HER2-targeted drugs with a CDK4/6 inhibitor before surgery for breast cancer that is both HER2-positive and ER-positive. It aims to see if this approach shrinks tumors more effectively and is safe.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
Hear when a new Breast Cancer - Infiltrating Ductal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.